{"id":"https://openalex.org/W4399667145","doi":"https://doi.org/10.1200/jco.2024.42.16_suppl.3120","title":"Results of a phase 1, dose-finding study of Debio 0123 as monotherapy in adult patients with advanced solid tumors: Safety, pharmacokinetic, and preliminary antitumor activity data.","display_name":"Results of a phase 1, dose-finding study of Debio 0123 as monotherapy in adult patients with advanced solid tumors: Safety, pharmacokinetic, and preliminary antitumor activity data.","publication_year":2024,"publication_date":"2024-06-01","ids":{"openalex":"https://openalex.org/W4399667145","doi":"https://doi.org/10.1200/jco.2024.42.16_suppl.3120"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2024.42.16_suppl.3120","doi":"https://doi.org/10.1200/jco.2024.42.16_suppl.3120","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2024.42.16_suppl.3120","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5022467575","display_name":"Kyriakos P. Papadopoulos","orcid":"https://orcid.org/0000-0002-0667-2620","observed_orcids":["https://orcid.org/0000-0002-0667-2620"]},"institutions":[{"id":"https://openalex.org/I4210119066","display_name":"South Texas Accelerated Research Therapeutics","ror":"https://ror.org/01scs7915","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210119066"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kyriakos P. Papadopoulos","raw_affiliation_strings":["START-San Antonio, San Antonio, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"START-San Antonio, San Antonio, TX","institution_ids":["https://openalex.org/I4210119066"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101836399","display_name":"Manish R. Sharma","orcid":"https://orcid.org/0000-0002-6711-1552","observed_orcids":["https://orcid.org/0000-0002-6711-1552"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Manish Sharma","raw_affiliation_strings":["START Midwest, Grand Rapids, MI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"START Midwest, Grand Rapids, MI","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089297467","display_name":"Reinhard Dummer","orcid":"https://orcid.org/0000-0002-2279-6906","observed_orcids":["https://orcid.org/0000-0002-2279-6906"]},"institutions":[{"id":"https://openalex.org/I4210100468","display_name":"University Hospital Zurich","ror":"https://ror.org/01462r250","country_code":"CH","type":"healthcare","lineage":["https://openalex.org/I4210100468"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Reinhard Dummer","raw_affiliation_strings":["University Hospital Zurich, Z\u00fcrich, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University Hospital Zurich, Z\u00fcrich, Switzerland","institution_ids":["https://openalex.org/I4210100468"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043295654","display_name":"Ilaria Colombo","orcid":"https://orcid.org/0000-0002-0602-8667","observed_orcids":["https://orcid.org/0000-0002-0602-8667"]},"institutions":[{"id":"https://openalex.org/I4404532900","display_name":"Istituto Oncologico della Svizzera Italiana","ror":"https://ror.org/04tty5b50","country_code":"CH","type":"healthcare","lineage":["https://openalex.org/I4210095212","https://openalex.org/I4404532900"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Ilaria Colombo","raw_affiliation_strings":["Oncology Institute of Southern Switzerland, Bellinzona, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology Institute of Southern Switzerland, Bellinzona, Switzerland","institution_ids":["https://openalex.org/I4404532900"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013521399","display_name":"Egle Ramelyte","orcid":"https://orcid.org/0000-0001-8262-8608","observed_orcids":["https://orcid.org/0000-0001-8262-8608"]},"institutions":[{"id":"https://openalex.org/I4210100468","display_name":"University Hospital Zurich","ror":"https://ror.org/01462r250","country_code":"CH","type":"healthcare","lineage":["https://openalex.org/I4210100468"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Egle Ramelyte","raw_affiliation_strings":["Department of Dermatology, University Hospital of Zurich, Z\u00fcrich, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, University Hospital of Zurich, Z\u00fcrich, Switzerland","institution_ids":["https://openalex.org/I4210100468"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030705960","display_name":"Leigh G. Seamon","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Leigh Seamon","raw_affiliation_strings":["START Midwest, Grand Rapids, MI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"START Midwest, Grand Rapids, MI","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073134832","display_name":"Drew Warren Rasco","orcid":"https://orcid.org/0009-0009-6619-2854","observed_orcids":["https://orcid.org/0009-0009-6619-2854"]},"institutions":[{"id":"https://openalex.org/I4210119066","display_name":"South Texas Accelerated Research Therapeutics","ror":"https://ror.org/01scs7915","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210119066"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Drew W. Rasco","raw_affiliation_strings":["START San Antonio, San Antonio, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"START San Antonio, San Antonio, TX","institution_ids":["https://openalex.org/I4210119066"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041379423","display_name":"Victor Rodriguez Freixinos","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210095057","display_name":"Debiopharm (Switzerland)","ror":"https://ror.org/00nxzrk14","country_code":"CH","type":"company","lineage":["https://openalex.org/I4210095057"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Victor Rodriguez Freixinos","raw_affiliation_strings":["Debiopharm International SA, Lausanne, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Debiopharm International SA, Lausanne, Switzerland","institution_ids":["https://openalex.org/I4210095057"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056855072","display_name":"Vito Dozio","orcid":"https://orcid.org/0000-0002-3782-2599","observed_orcids":["https://orcid.org/0000-0002-3782-2599"]},"institutions":[{"id":"https://openalex.org/I4210095057","display_name":"Debiopharm (Switzerland)","ror":"https://ror.org/00nxzrk14","country_code":"CH","type":"company","lineage":["https://openalex.org/I4210095057"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Vito Dozio","raw_affiliation_strings":["Debiopharm International SA, Lausanne, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Debiopharm International SA, Lausanne, Switzerland","institution_ids":["https://openalex.org/I4210095057"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003538871","display_name":"Tri Tat","orcid":"https://orcid.org/0009-0004-6837-8277","observed_orcids":["https://orcid.org/0009-0004-6837-8277"]},"institutions":[{"id":"https://openalex.org/I4210095057","display_name":"Debiopharm (Switzerland)","ror":"https://ror.org/00nxzrk14","country_code":"CH","type":"company","lineage":["https://openalex.org/I4210095057"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Tri Tat","raw_affiliation_strings":["Debiopharm International SA, Lausanne, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Debiopharm International SA, Lausanne, Switzerland","institution_ids":["https://openalex.org/I4210095057"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031240431","display_name":"Noemie Luong","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210095057","display_name":"Debiopharm (Switzerland)","ror":"https://ror.org/00nxzrk14","country_code":"CH","type":"company","lineage":["https://openalex.org/I4210095057"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Noemie Luong","raw_affiliation_strings":["Debiopharm International SA, Lausanne, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Debiopharm International SA, Lausanne, Switzerland","institution_ids":["https://openalex.org/I4210095057"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5099127488","display_name":"Aliaksandr Hurynovich","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210095057","display_name":"Debiopharm (Switzerland)","ror":"https://ror.org/00nxzrk14","country_code":"CH","type":"company","lineage":["https://openalex.org/I4210095057"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Aliaksandr Hurynovich","raw_affiliation_strings":["Debiopharm International SA, Lausanne, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Debiopharm International SA, Lausanne, Switzerland","institution_ids":["https://openalex.org/I4210095057"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075834401","display_name":"Mokhtar Omar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210095057","display_name":"Debiopharm (Switzerland)","ror":"https://ror.org/00nxzrk14","country_code":"CH","type":"company","lineage":["https://openalex.org/I4210095057"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Mokhtar Omar","raw_affiliation_strings":["Debiopharm International SA, Lausanne, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Debiopharm International SA, Lausanne, Switzerland","institution_ids":["https://openalex.org/I4210095057"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023775622","display_name":"Sandrine Micallef","orcid":"https://orcid.org/0000-0002-6172-5246","observed_orcids":["https://orcid.org/0000-0002-6172-5246"]},"institutions":[{"id":"https://openalex.org/I4210095057","display_name":"Debiopharm (Switzerland)","ror":"https://ror.org/00nxzrk14","country_code":"CH","type":"company","lineage":["https://openalex.org/I4210095057"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Sandrine Micallef","raw_affiliation_strings":["Debiopharm International SA, Lausanne, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Debiopharm International SA, Lausanne, Switzerland","institution_ids":["https://openalex.org/I4210095057"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111964426","display_name":"Anne Bellon","orcid":"https://orcid.org/0009-0006-4723-0550","observed_orcids":["https://orcid.org/0009-0006-4723-0550"]},"institutions":[{"id":"https://openalex.org/I4210095057","display_name":"Debiopharm (Switzerland)","ror":"https://ror.org/00nxzrk14","country_code":"CH","type":"company","lineage":["https://openalex.org/I4210095057"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Anne Bellon","raw_affiliation_strings":["Debiopharm International SA, Lausanne, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Debiopharm International SA, Lausanne, Switzerland","institution_ids":["https://openalex.org/I4210095057"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071821451","display_name":"Esteban Rodrigo Imedio","orcid":"https://orcid.org/0000-0001-5666-666X","observed_orcids":["https://orcid.org/0000-0001-5666-666X"]},"institutions":[{"id":"https://openalex.org/I4210095057","display_name":"Debiopharm (Switzerland)","ror":"https://ror.org/00nxzrk14","country_code":"CH","type":"company","lineage":["https://openalex.org/I4210095057"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Esteban Rodrigo Imedio","raw_affiliation_strings":["Debiopharm International SA, Lausanne, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Debiopharm International SA, Lausanne, Switzerland","institution_ids":["https://openalex.org/I4210095057"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5048622832","display_name":"Anastasios Stathis","orcid":"https://orcid.org/0000-0002-2859-7529","observed_orcids":["https://orcid.org/0000-0002-2859-7529"]},"institutions":[{"id":"https://openalex.org/I4404532900","display_name":"Istituto Oncologico della Svizzera Italiana","ror":"https://ror.org/04tty5b50","country_code":"CH","type":"healthcare","lineage":["https://openalex.org/I4210095212","https://openalex.org/I4404532900"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Anastasios Stathis","raw_affiliation_strings":["Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland","institution_ids":["https://openalex.org/I4404532900"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":10,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"42","issue":"16_suppl","first_page":"3120","last_page":"3120"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.2856000065803528,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.2856000065803528,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10583","display_name":"Cancer-related Molecular Pathways","score":0.257099986076355,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.05260000005364418,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/wee1-inhibitor","display_name":"WEE1 inhibitor","score":0.9509999752044678},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.8830000162124634},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8050000071525574},{"id":"https://openalex.org/keywords/recommended-phase-ii-dose","display_name":"recommended phase 2 dose","score":0.9259999990463257},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.8259999752044678},{"id":"https://openalex.org/keywords/fatigue","display_name":"fatigue","score":0.8040000200271606},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.6970000267028809},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.9290000200271606},{"id":"https://openalex.org/keywords/ovarian-cancer","display_name":"ovarian cancer","score":0.5590000152587891},{"id":"https://openalex.org/keywords/colon-cancer","display_name":"colon cancer","score":0.7260000109672546},{"id":"https://openalex.org/keywords/mitotic-catastrophe","display_name":"mitotic catastrophe","score":0.6159999966621399},{"id":"https://openalex.org/keywords/brain-penetrant-drugs","display_name":"brain-penetrant drugs","score":0.656000018119812},{"id":"https://openalex.org/keywords/monotherapy","display_name":"monotherapy","score":0.6240000128746033},{"id":"https://openalex.org/keywords/bayesian-logistic-regression","display_name":"Bayesian logistic regression","score":0.42100000381469727}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8601105809211731},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6409383416175842},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4878807067871094},{"id":"https://openalex.org/C3018359032","wikidata":"https://www.wikidata.org/wiki/Q1550789","display_name":"Safety profile","level":3,"score":0.4409814774990082},{"id":"https://openalex.org/C2993640289","wikidata":"https://www.wikidata.org/wiki/Q1216998","display_name":"Solid tumor","level":3,"score":0.43409064412117004},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3860771954059601},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.374740868806839},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.23986312747001648},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.15199768543243408}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2024.42.16_suppl.3120","doi":"https://doi.org/10.1200/jco.2024.42.16_suppl.3120","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2024.42.16_suppl.3120","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F7393263434","display_name":"Debiopharm","ror":"https://ror.org/00nxzrk14"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7161152450","https://openalex.org/W4281788755","https://openalex.org/W4410822525","https://openalex.org/W4379282503","https://openalex.org/W4402560057","https://openalex.org/W7162671278","https://openalex.org/W4402560016","https://openalex.org/W4388589208","https://openalex.org/W2598815487","https://openalex.org/W2126578811"],"abstract_inverted_index":{"3120":[0],"Background:":[1],"Debio":[2,37,65,85,110,178,286,406,416,446],"0123":[3,38,86,111,179,287,407,417],"is":[4,68,108,112,136],"an":[5],"oral,":[6],"brain-penetrant,":[7],"highly":[8],"selective":[9],"WEE1":[10,12],"inhibitor.":[11],"inhibition":[13,43],"leads":[14],"to":[15,30,137,185,270,296],"S":[16],"phase":[17,70],"and":[18,33,54,80,144,199,208,244,260,281,362,397,425,434,442],"G2/M":[19],"cell":[20,35,52],"cycle":[21],"checkpoint":[22],"abrogation,":[23],"permitting":[24],"mitosis":[25],"without":[26],"DNA":[27],"repair,":[28],"leading":[29],"mitotic":[31],"catastrophe":[32],"subsequent":[34],"death.":[36],"has":[39,420],"demonstrated":[40],"significant":[41],"growth":[42],"in":[44,46,57,59,87,276,315,365],"vitro":[45],"a":[47,69,119,123,322,421],"broad":[48],"range":[49],"of":[50,84,133,152,311,324,329,353,385,405,415,445],"cancer":[51],"lines":[53],"antitumor":[55,82,443],"activity":[56,83,444],"vivo":[58],"human":[60],"xenograft":[61],"tumor":[62,342],"models.":[63],"Methods:":[64],"0123-102":[66],"(NCT05109975)":[67],"1":[71,381],"dose-escalation":[72],"study":[73,135],"evaluating":[74],"the":[75,139,337,366,380,440],"safety,":[76,394],"tolerability,":[77],"pharmacokinetics":[78],"(PKs)":[79],"preliminary":[81],"patients":[88],"(pts)":[89],"with":[90,160,292,299,340],"advanced":[91],"solid":[92],"tumors":[93],"who":[94],"have":[95],"recurred":[96],"or":[97,274],"progressed":[98],"following":[99],"prior":[100],"therapy":[101,107],"and/or":[102],"for":[103],"whom":[104],"no":[105],"standard":[106],"available.":[109],"given":[113],"as":[114,350,369,410,418],"monotherapy,":[115],"once":[116,403],"daily,":[117],"over":[118],"21-day":[120],"cycle,":[121],"using":[122],"Bayesian":[124],"Logistic":[125],"Regression":[126],"Model-guided":[127],"dose":[128,191,271,293,323,375],"escalation.":[129],"The":[130,214,221,247],"primary":[131,172],"objective":[132],"this":[134],"determine":[138],"Maximum":[140],"Tolerated":[141],"Dose":[142,148],"(MTD)":[143],"Recommended":[145],"Phase":[146],"2":[147,161,282],"(RP2D).":[149],"Results:":[150],"As":[151],"October":[153],"24,":[154],"2023,":[155],"27":[156],"pts":[157,162,189,339,346,359,387],"were":[158,230,253],"treated":[159],"ongoing":[163],"(67%":[164],"female,":[165],"mean":[166],"age":[167],"63":[168],"years;":[169],"most":[170,222,248],"common":[171,249],"tumors:":[173],"ovarian":[174,358],"[33%],":[175],"colon":[176],"[18%]).":[177],"was":[180,216,318,331,408],"escalated":[181],"from":[182,294,321,377],"30":[183],"mg":[184,402],"350":[186,206,297],"mg.":[187,220,326],"Three":[188],"had":[190,347,388],"limiting":[192],"toxicities":[193],"(DLTs)":[194],"[Grade":[195],"(Gr)":[196],"3":[197,252],"fatigue":[198,245,261],"Gr3":[200,209],"Fridericia-corrected":[201],"QT":[202],"(QTcF)":[203],"prolongation":[204,236,255],"at":[205,211,218],"mg,":[207,298],"rash":[210],"260":[212,219,401],"mg].":[213],"MTD":[215],"determined":[217],"frequent":[223],"treatment":[224,330],"related":[225],"adverse":[226,267],"events":[227,268],"(TRAEs)":[228],"(\u226520%)":[229],"blood":[231],"creatinine":[232],"increased":[233,290],"(37%),":[234,237],"QTcF":[235,254],"nausea":[238],"(33%),":[239],"vomiting":[240],"(26%),":[241],"dysgeusia":[242],"(22%)":[243],"(22%).":[246],"TRAEs":[250],"Gr\u2265":[251],"(n":[256,262],"=":[257,263],"3,":[258],"11%)":[259],"2,":[264],"7%).":[265],"Retalted":[266],"led":[269],"interruptions,":[272],"reductions,":[273],"discontinuations":[275],"6":[277,332],"(22%),":[278],"4":[279],"(15%)":[280],"(7%)":[283],"pts,":[284],"respectively.":[285],"plasma":[288],"exposure":[289],"proportionally":[291],"150":[295],"steady":[300],"state":[301],"achieved":[302,360],"after":[303],"15-21":[304],"days.":[305],"Target":[306],"engagement,":[307],"assessed":[308],"by":[309],"reduction":[310,364],"phosphorylated":[312],"CDC2":[313],"levels":[314],"skin":[316],"biopsies,":[317],"observed":[319],"consistently":[320],"200":[325],"Median":[327],"duration":[328],"weeks":[333,355],"(3-30":[334],"weeks).":[335],"Of":[336],"25":[338],"post-baseline":[341],"assessment,":[343],"8":[344],"(32%)":[345],"stable":[348],"disease":[349],"best":[351],"response":[352],"\u22655":[354],"duration.":[356],"Two":[357],"17%":[361],"20%":[363],"target":[367],"lesions":[368],"per":[370],"RECIST":[371],"1.1,":[372],"despite":[373],"requiring":[374],"reductions":[376],"350mg":[378],"during":[379],"st":[382],"cycle.":[383],"One":[384],"these":[386],"CA-125":[389],"response.":[390],"Based":[391],"on":[392],"cumulative":[393],"exposure-response":[395],"data,":[396],"additional":[398],"PK":[399],"modeling,":[400],"daily":[404],"selected":[409],"RP2D.":[411],"Conclusions:":[412],"Continuous":[413],"dosing":[414],"monotherapy":[419],"manageable":[422],"safety":[423,441],"profile":[424],"linear":[426],"pharmacokinetics.":[427],"A":[428],"multi":[429],"cohort":[430],"expansion,":[431],"including":[432],"biomarker-selected":[433],"unselected":[435],"cohorts,":[436],"will":[437],"further":[438],"evaluate":[439],"0123.":[447],"Clinical":[448],"trial":[449],"information:":[450],"NCT05109975":[451],".":[452]},"counts_by_year":[{"year":2026,"cited_by_count":5},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2024-06-15T00:00:00"}